ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
Madan JagasiaAleksander LazaryanCarlos R BachierAmandeep SalhotraDaniel J WeisdorfBehyar ZoghiJames EssellLaurie GreenOlivier SchuellerJeegar PatelAlexandra Zanin-ZhorovJonathan M WeissZhongming YangDavid EiznhamerSanjay K AggarwalBruce R BlazarStephanie J LeePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Belumosudil treatment resulted in a high ORR and overall survival rate and demonstrated quality-of-life improvements, CS dose reductions, and limited toxicity. Data from the study indicated that belumosudil may prove to be an effective therapy for patients with treatment-refractory cGVHD.
Keyphrases